Full results from the OlympiA Phase III, multicenter trial promise to extend the use of PARPi olaparib as adjuvant therapy…
Judit Balmaña
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
